melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 

theraTRACE

Melior Pharmaceuticals

 

                                                                  

melior

Melior Discovery publications

 
   

 

Rule of Five in 2015 and Beyond:  Target and Ligand Structural Limitations, Ligand Chemistry Structure and Drug Discovery Project Decisions

Christopher A. Lipinski

Science Direct, Elsevier, April 27, 2016

 

melior

Parallel Worlds of Public and Commercial Bioactivity Chemistry Data

Lipinski CA, Litterman NK, Southan C, Williams AJ, Clark AM and Ekins S. 

J. Med. Chem. 2014 Nov; Article ASAP.

 

melior

Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes Litterman NK, Lipinski CA, Bunin BA, Ekins S. J. Chem. Inf. Model., 2014 Sept; 54(10): 2996-3004.

 

melior

The future of drug discovery: Two required supplements to current practices. Reaume AG, Lipinski CA. Pharma July 2013
melior
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG. J Pharmacol Exp Ther. 2012 Jul;342(1):15-22.
melior
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32.
melior
Phenotypic in vivo screening to identify new unpredicted indication for existing drugs and drug candidates. Saporito MS, Lipinski CA, Reaume AG in Drug Repositioning: Bringing New Life to Shelved Assets. (John Wiley & Sons, Hoboken, NJ, USA) 2012. Barratt MD and Frail D (Eds).
melior
Drug repurposing through nonhypothesis driven phenotypic screening. Reaume AG. Drug Disc. Today 2011 8(3-4):85-88.
melior
theraTRACE®: A mechanism unbiased in vivo platform for phenotypic screening and frug repositioning. Saporito MS, Reaume AG. Drug Disc. Today 2011 8(3-4):89-95.
melior
The anti-intellectual effects of intellectual property. Lipinski CA. Curr Opin Chem Biol. 2006 Aug;10(4):380-3.
melior

If you are interested in learning more about Melior Publications, please contact bizdev@meliordiscovery.com to start the conversation.

Back to top of page